Cargando…

SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays

This study measured antibodies against different antigen targets in healthcare workers (HCW) who have been fully vaccinated with mRNA vaccines, recovered from natural infection, or patients during active infection. All vaccinated individuals were positive for anti-RBD, anti-S1, and anti-S2 antibodie...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyers, Jamie, Windau, Anne, Schmotzer, Christine, Saade, Elie, Noguez, Jaime, Stempak, Lisa, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420072/
https://www.ncbi.nlm.nih.gov/pubmed/36162282
http://dx.doi.org/10.1016/j.diagmicrobio.2022.115803
_version_ 1784777311650840576
author Meyers, Jamie
Windau, Anne
Schmotzer, Christine
Saade, Elie
Noguez, Jaime
Stempak, Lisa
Zhang, Xiaochun
author_facet Meyers, Jamie
Windau, Anne
Schmotzer, Christine
Saade, Elie
Noguez, Jaime
Stempak, Lisa
Zhang, Xiaochun
author_sort Meyers, Jamie
collection PubMed
description This study measured antibodies against different antigen targets in healthcare workers (HCW) who have been fully vaccinated with mRNA vaccines, recovered from natural infection, or patients during active infection. All vaccinated individuals were positive for anti-RBD, anti-S1, and anti-S2 antibodies. The nonvaccinated recovered cohort showed 90% seropositivity by Atellica total antibody, 73% by Atellica IgG, 84% by Bioplex anti-RBD, 77% by Bioplex anti-S1, 37% by Bioplex anti-S2, and 79% by Bioplex antinucleocapsid respectively. The active infection cohort exhibited a similar pattern as the recovered cohort. About 88% and 78% of the recovered and active infection cohort produced both anti-spike and anti-N antibodies with Anti-S1/anti-N ratios ranging from 0.07 to 16.26. In summary, fully vaccinated individuals demonstrated an average of 50-fold higher antibody levels than naturally infected unvaccinated individuals with immune reactivity strongly towards RBD/S1 and a weak response to S2. The results support vaccination regardless of previous COVID-infection status.
format Online
Article
Text
id pubmed-9420072
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-94200722022-08-30 SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays Meyers, Jamie Windau, Anne Schmotzer, Christine Saade, Elie Noguez, Jaime Stempak, Lisa Zhang, Xiaochun Diagn Microbiol Infect Dis Article This study measured antibodies against different antigen targets in healthcare workers (HCW) who have been fully vaccinated with mRNA vaccines, recovered from natural infection, or patients during active infection. All vaccinated individuals were positive for anti-RBD, anti-S1, and anti-S2 antibodies. The nonvaccinated recovered cohort showed 90% seropositivity by Atellica total antibody, 73% by Atellica IgG, 84% by Bioplex anti-RBD, 77% by Bioplex anti-S1, 37% by Bioplex anti-S2, and 79% by Bioplex antinucleocapsid respectively. The active infection cohort exhibited a similar pattern as the recovered cohort. About 88% and 78% of the recovered and active infection cohort produced both anti-spike and anti-N antibodies with Anti-S1/anti-N ratios ranging from 0.07 to 16.26. In summary, fully vaccinated individuals demonstrated an average of 50-fold higher antibody levels than naturally infected unvaccinated individuals with immune reactivity strongly towards RBD/S1 and a weak response to S2. The results support vaccination regardless of previous COVID-infection status. Elsevier Inc. 2022-12 2022-08-28 /pmc/articles/PMC9420072/ /pubmed/36162282 http://dx.doi.org/10.1016/j.diagmicrobio.2022.115803 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Meyers, Jamie
Windau, Anne
Schmotzer, Christine
Saade, Elie
Noguez, Jaime
Stempak, Lisa
Zhang, Xiaochun
SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
title SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
title_full SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
title_fullStr SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
title_full_unstemmed SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
title_short SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
title_sort sars-cov-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420072/
https://www.ncbi.nlm.nih.gov/pubmed/36162282
http://dx.doi.org/10.1016/j.diagmicrobio.2022.115803
work_keys_str_mv AT meyersjamie sarscov2antibodyprofileofnaturallyinfectedandvaccinatedindividualsdetectedusingqualitativesemiquantitativeandmultipleximmunoassays
AT windauanne sarscov2antibodyprofileofnaturallyinfectedandvaccinatedindividualsdetectedusingqualitativesemiquantitativeandmultipleximmunoassays
AT schmotzerchristine sarscov2antibodyprofileofnaturallyinfectedandvaccinatedindividualsdetectedusingqualitativesemiquantitativeandmultipleximmunoassays
AT saadeelie sarscov2antibodyprofileofnaturallyinfectedandvaccinatedindividualsdetectedusingqualitativesemiquantitativeandmultipleximmunoassays
AT noguezjaime sarscov2antibodyprofileofnaturallyinfectedandvaccinatedindividualsdetectedusingqualitativesemiquantitativeandmultipleximmunoassays
AT stempaklisa sarscov2antibodyprofileofnaturallyinfectedandvaccinatedindividualsdetectedusingqualitativesemiquantitativeandmultipleximmunoassays
AT zhangxiaochun sarscov2antibodyprofileofnaturallyinfectedandvaccinatedindividualsdetectedusingqualitativesemiquantitativeandmultipleximmunoassays